

Attorney Docket No.: DEX-0079  
Inventors: Burczak and Wilkinson  
Serial No.: 09/622,776  
Filing Date: August 23, 2000  
Page 2

In the Specification:

At page 1, please replace the paragraph at lines 5 through 10 with the following:

*A1*  
This application is the National Stage of International Application no. PCT/US99/03170, filed February 12, 1999, which is continuation of U.S. Application Serial No. 09/175,504, now abandoned, filed October 20, 1998, which is a continuation-in-part of U.S. Application Serial No. 09/111,938, now abandoned filed July 8, 1998, which claims the benefit of priority from U.S. Provisional Application Serial No. 60/075,504, filed February 23, 1998. --

In the Claims:

Please cancel claims 4 and 9.

Please amend the claims as follows:

- A2*
1. (amended) A method of monitoring a cancer in a patient which has not metastasized for the onset of metastasis comprising:
    - (a) identifying a patient having a cancer that is not known to have metastasized;
    - (b) periodically analyzing a sample of bodily fluid from the patient for PLA<sub>2</sub>; and
    - (c) detecting levels of PLA<sub>2</sub> with an enzyme level cut-off of 4.5 ng/ml, in the sample of bodily fluid obtained from the

Attorney Docket No.: **DEX-0079**  
Inventors: **Burczak and Wilkinson**  
Serial No.: **09/622,776**  
Filing Date: **August 23, 2000**  
Page 3

*A2*  
*cont* patient wherein elevated levels of PLA<sub>2</sub> in a sample of bodily fluid  
are indicative of onset of metastasis of the cancer.

*A3*  
6. (amended) A method of diagnosing a metastatic cancer in  
a patient comprising:

(a) obtaining a sample of biological fluid from a  
patient; and  
(b) detecting the level of PLA<sub>2</sub> with an enzyme level cut-  
off of 4.5 ng/ml, in a sample of biological fluid wherein elevated  
levels of PLA<sub>2</sub> in the sample are indicative of metastatic cancer.

10. (amended) A method of diagnosing ovarian or testicular  
cancer in a patient comprising:

*A4*  
(a) obtaining a sample of biological fluid from a  
patient; and  
*A5* (b) detecting levels of PLA<sub>2</sub> in the sample; wherein  
elevated levels of PLA<sub>2</sub> in the sample are indicative of ovarian or  
testicular cancer.

13. (amended) A method of monitoring progression, remission,  
response to therapy and stabilization of prostate, breast, ovarian  
or testicular cancer in a patient comprising measuring PLA<sub>2</sub> levels  
with an enzyme level cut-off of 4.5 ng/ml, in biological fluids  
obtained from a patient at selected times wherein an increase in  
the measured levels of PLA<sub>2</sub> over time is indicative of progressive